Krebs Biochemicals & Industries Ltd

₹ 67.0 -0.19%

09 Jun - close price

krebsbiochem.com BSE: 524518 NSE: KREBSBIO

About

Incorporated in 1991, Krebs Biochemicals & Industries Ltd is presently engaged in manufacturing of active pharmaceutical ingredients.

Key Points

Product Portfolio
a) Androstenedione which is used as Steroid Intermediate
b) Lovastatin used as Anti-cholesterol medication
c) Simvastatin is also used as Anti-cholesterol medication
d) Upcoming Products: Amlodipine, Cetirizine, Orlistat, Telmisartan, Serratiopepetidase and Phenylephrine. ^[1]

Website BSE NSE

Market Cap ₹ 146 Cr.
Current Price ₹ 67.0
High / Low ₹ 104 / 38.3
Stock P/E
Book Value ₹ -75.5
Dividend Yield 0.00 %
ROCE -15.4 %
ROE %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Cons

Company has low interest coverage ratio.
The company has delivered a poor sales growth of -15.1% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Figures in Rs. Crores

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	11.46	10.58	14.89	12.98	11.97	12.89	12.86	11.47	6.10	5.48	4.17	7.27	6.81
	16.08	13.20	15.79	15.07	15.09	15.08	15.58	16.18	11.51	7.57	6.97	6.97	7.67
Operating Profit	-4.62	-2.62	-0.90	-2.09	-3.12	-2.19	-2.72	-4.71	-5.41	-2.09	-2.80	0.30	-0.86
OPM %	-40.31%	-24.76%	-6.04%	-16.10%	-26.07%	-16.99%	-21.15%	-41.06%	-88.69%	-38.14%	-67.15%	4.13%	-12.63%
	0.19	0.04	0.17	0.03	0.21	0.03	0.09	0.25	0.34	0.01	0.01	0.00	2.00
Interest	1.03	1.10	1.13	1.19	1.27	1.32	1.42	1.56	1.61	1.65	1.73	1.79	1.91
Depreciation	1.48	1.65	1.71	1.73	1.67	1.69	1.71	1.72	1.57	1.60	1.62	1.63	1.57
Profit before tax	-6.94	-5.33	-3.57	-4.98	-5.85	-5.17	-5.76	-7.74	-8.25	-5.33	-6.14	-3.12	-2.34
Tax %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.24%	0.00%	0.00%	0.00%	0.00%
	-6.94	-5.33	-3.57	-4.98	-5.85	-5.17	-5.76	-7.74	-8.27	-5.32	-6.14	-3.13	-2.34
EPS in Rs	-3.22	-2.47	-1.66	-2.31	-2.71	-2.40	-2.67	-3.59	-3.84	-2.47	-2.85	-1.45	-1.09
Raw PDF

Profit & Loss

Figures in Rs. Crores

	Mar 2015 6m	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	0	1	3	34	48	33	54	60	52	50	43	24
	5	14	11	41	58	52	71	94	68	59	58	29
Operating Profit	-5	-12	-8	-8	-10	-19	-18	-34	-16	-9	-15	-5
OPM %		-1,088%	-248%	-22%	-20%	-56%	-33%	-57%	-30%	-17%	-35%	-23%
	3	1	-0	-1	0	0	1	1	1	0	1	2
Interest	4	1	3	5	6	6	6	5	3	5	6	7
Depreciation	2	4	4	4	4	5	5	6	7	7	7	6
Profit before tax	-8	-16	-16	-18	-20	-29	-28	-45	-25	-20	-27	-17
Tax %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	-8	-16	-16	-18	-20	-29	-28	-45	-25	-20	-27	-17
EPS in Rs	-6.82	-10.33	-9.67	-10.73	-12.03	-16.04	-14.45	-20.65	-11.45	-9.15	-12.50	-7.85
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Compounded Sales Growth
10 Years:	35%
5 Years:	-15%
3 Years:	-23%
TTM:	-45%

Compounded Profit Growth
10 Years:	0%
5 Years:	7%
3 Years:	10%
TTM:	37%

Stock Price CAGR
10 Years:	-3%
5 Years:	-12%
3 Years:	-1%
1 Year:	-29%

Return on Equity
10 Years:	%
5 Years:	%
3 Years:	%
Last Year:	%

Balance Sheet

Figures in Rs. Crores

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	10	13	14	14	17	18	20	22	22	22	22	22
Reserves	9	-0	-12	-32	-31	-43	-62	-97	-121	-141	-168	-184
	61	31	48	56	53	66	111	143	183	194	212	225
	29	73	73	87	103	93	91	122	91	104	103	101
Total Liabilities	108	116	122	126	142	134	159	190	175	178	169	163
	58	93	102	101	101	105	118	139	147	150	146	142
CWIP	0	11	4	4	3	4	12	8	4	2	3	2
Investments	0	0	0	0	0	0	0	0	0	0	0	0
	50	13	16	21	38	24	29	43	24	26	20	20
Total Assets	108	116	122	126	142	134	159	190	175	178	169	163

Cash Flows

Figures in Rs. Crores

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-45	-15	-11	-6	4	-36	-15	-17	-25	2	-8	-2
	-3	-4	-5	-3	-4	-10	-23	-23	-13	-8	-5	-4
	54	13	16	9	17	29	38	40	37	6	13	6
Net Cash Flow	6	-6	-0	0	17	-17	1	-1	-0	0	0	-0
Free Cash Flow	-48	-23	-17	-9	-1	-45	-40	-41	-36	-5	-11	-5
CFO/OP	924%	123%	140%	83%	-40%	191%	83%	51%	157%	-27%	52%	35%

Ratios

Figures in Rs. Crores

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days		10	180	3	22	2	2	5	4	14	0	0
Inventory Days		14,704	2,162	337	142	345	234	230	170	543	396
Days Payable		32,250	4,360	510	339	521	292	340	217	1,051	1,192
Cash Conversion Cycle		-17,536	-2,018	-170	-175	-174	-57	-106	-44	-494	-795	0
Working Capital Days		-6,532	-2,132	-275	-315	-267	-187	-261	-232	-322	-787	-1,593
ROCE %	-8%	-26%	-26%	-26%	-36%	-57%	-40%	-57%	-29%	-19%	-30%	-15%

Insights

In beta

Mar 2015

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Closing Inventory - Finished Goods (Total)
₹ Lakhs

xx.xx	xx.xx	xx.xx	xxx.xx	xx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	x.xx
x.xx	x.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx	x,xxx.xx	xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx
			xxx		xxx	xxx	xxx	xxx	xxx	xxx
	x.xx	x.xx	x.xx	x.xx

Please log in to see hidden values.

Revenue from Sale of Services (Contract Manufacturing/Job Work)
₹ Lakhs

Total Regular Employees
Number

Installed Capacity - Simvastatin (Anti-cholesterol)
MT per month

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%
	0.50%	0.50%	0.50%	0.50%	0.50%	0.50%	0.50%	0.50%	0.50%	0.50%	0.50%	0.50%
	26.77%	26.76%	26.77%	26.75%	26.75%	26.76%	26.76%	26.75%	26.76%	26.76%	26.76%	26.77%
No. of Shareholders	9,393	9,030	8,990	8,909	8,848	9,425	9,091	8,798	9,118	8,912	8,710	8,553

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	59.77%	59.77%	64.66%	67.35%	70.05%	72.74%	72.74%	72.74%	72.74%	72.74%
	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.50%	0.50%	0.50%	0.50%
	40.22%	40.22%	35.33%	32.64%	29.94%	27.25%	26.76%	26.75%	26.75%	26.77%
No. of Shareholders	5,787	5,093	5,019	4,804	6,400	9,531	9,315	8,909	8,798	8,553

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Krebs Biochemicals & Industries Ltd

Krebs Biochemicals & Industries Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Insights

Shareholding Pattern

Documents

Announcements

Annual reports